Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the updated response and survival data of a phase 1a study of the anti-PDL1 antibody, MPDL3280A, for the treatment of patients with metastatic urothelial bladder cancer.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.